Mapping Research Trends on Intestinal Permeability in Irritable Bowel Syndrome with a Focus on Nutrition: A Bibliometric Analysis
Nutrients · 2025
DOI: 10.3390/nu17061064 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, 2025. Verfasst von Domenica Mallardi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology-IRCCS "Saverio de Bellis", 70013 Castellana Grotte, Ital…. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Bibliometrics, Intestinal Mucosa, Biomedical Research. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health, Italian Ministry of Health RC 2024.
Abstract (Originalsprache)
Irritable Bowel Syndrome (IBS) is a complex gastrointestinal disorder characterized by chronic abdominal pain and altered bowel habits, often linked to disruptions in intestinal barrier function. Increased intestinal permeability plays a key role in IBS pathogenesis, affecting immune responses, gut microbiota, and inflammation. This study conducts a bibliometric analysis to explore global research trends on intestinal permeability in IBS, focusing on key contributors, collaboration networks, and thematic shifts, particularly the interplay between the intestinal barrier, gut microbiota, and dietary components. A total of 411 articles were retrieved from Scopus, with 232 studies analyzed using Bibliometrix in R. To optimize screening, ASReview, a machine learning tool, was employed, utilizing the Naïve Bayes algorithm combined with Term Frequency-Inverse Document Frequency (TF-IDF) for adaptive ranking of articles by relevance. This approach significantly improved screening step efficacy. The analysis highlights growing research interest, with China and the USA as leading contributors. Key themes include the role of gut microbiota in modulating permeability, the impact of dietary components (fiber, probiotics, bioactive compounds) on tight junction integrity, and the exploration of therapeutic agents. Emerging studies suggest integrating gut barrier modulation with nutritional and microbiome-targeted strategies for IBS management. This study provides a comprehensive overview of research on intestinal permeability in IBS, mapping its evolution and identifying major trends. By highlighting key contributors and thematic areas, it offers insights to guide future investigations into the interplay between gut permeability, diet, and microbiota, advancing understanding of IBS pathophysiology and management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology-IRCCS "Saverio de Bellis", 70013 Castellana Grotte, Italy.
- Data Science Unit, National Institute of Gastroenterology-IRCCS "Saverio de Bellis", 70013 Castellana Grotte, Italy.
ORCID-Profile: Domenica Mallardi, Davide Guido, Michelangelo Aloisio, Michele Linsalata, Francesco Russo
Förderung
- Italian Ministry of Health
- Italian Ministry of Health RC 2024
Zitieren
APA
Mallardi, D., Maqoud, F., Guido, D., Aloisio, M., Linsalata, M., & Russo, F. (2025). Mapping Research Trends on Intestinal Permeability in Irritable Bowel Syndrome with a Focus on Nutrition: A Bibliometric Analysis. Nutrients. https://doi.org/10.3390/nu17061064
Vancouver
Mallardi D, Maqoud F, Guido D, Aloisio M, Linsalata M, Russo F. Mapping Research Trends on Intestinal Permeability in Irritable Bowel Syndrome with a Focus on Nutrition: A Bibliometric Analysis. Nutrients. 2025. doi:10.3390/nu17061064
BibTeX
@article{Mallardi2025,
author = {Mallardi, Domenica and Maqoud, Fatima and Guido, Davide and Aloisio, Michelangelo and Linsalata, Michele and Russo, Francesco},
title = {Mapping Research Trends on Intestinal Permeability in Irritable Bowel Syndrome with a Focus on Nutrition: A Bibliometric Analysis},
journal = {Nutrients},
year = {2025},
doi = {10.3390/nu17061064}
}
EUVIMED